Induction of mediator release from human glomerular mesangial cells by the terminal complement components C5b-9. 1991

M Schönermark, and R Deppisch, and G Riedasch, and K Rother, and G M Hänsch
Institut für Immunologie und Serologie, Universität Heidelberg, BRD.

Exposure of cultured human glomerular mesangial cells (GMC) to normal human serum and an activator of the complement system results in rapid uptake of the terminal complement proteins C5b-9 by the cells. This 'innocent bystander' complement attack, however, does not result in cell killing, but in the stimulation of the GMC to release prostaglandin E (PGE), interleukin 1 (Il-1) and tumor necrosis factor (TNF). Endogenously synthesized Il-1 in turn activates PGE release, indicating that the C5b-9 attack initiates an autocrine feedback stimulation. Together with the fact that C5b-9 is found in many forms of glomerulonephritis, the data point to a role of the terminal complement proteins in the initiation and perpetuation of an inflammatory response.

UI MeSH Term Description Entries
D007375 Interleukin-1 A soluble factor produced by MONOCYTES; MACROPHAGES, and other cells which activates T-lymphocytes and potentiates their response to mitogens or antigens. Interleukin-1 is a general term refers to either of the two distinct proteins, INTERLEUKIN-1ALPHA and INTERLEUKIN-1BETA. The biological effects of IL-1 include the ability to replace macrophage requirements for T-cell activation. IL-1,Lymphocyte-Activating Factor,Epidermal Cell Derived Thymocyte-Activating Factor,Interleukin I,Macrophage Cell Factor,T Helper Factor,Epidermal Cell Derived Thymocyte Activating Factor,Interleukin 1,Lymphocyte Activating Factor
D011458 Prostaglandins E (11 alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-en-1-oic acid (PGE(1)); (5Z,11 alpha,13E,15S)-11,15-dihydroxy-9-oxoprosta-5,13-dien-1-oic acid (PGE(2)); and (5Z,11 alpha,13E,15S,17Z)-11,15-dihydroxy-9-oxoprosta-5,13,17-trien-1-oic acid (PGE(3)). Three of the six naturally occurring prostaglandins. They are considered primary in that no one is derived from another in living organisms. Originally isolated from sheep seminal fluid and vesicles, they are found in many organs and tissues and play a major role in mediating various physiological activities. PGE
D005920 Glomerular Mesangium The thin membranous structure supporting the adjoining glomerular capillaries. It is composed of GLOMERULAR MESANGIAL CELLS and their EXTRACELLULAR MATRIX. Mesangium, Glomerular,Mesangial Extracellular Matrix,Extracellular Matrices, Mesangial,Extracellular Matrix, Mesangial,Glomerular Mesangiums,Matrices, Mesangial Extracellular,Matrix, Mesangial Extracellular,Mesangial Extracellular Matrices,Mesangiums, Glomerular
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015938 Complement Membrane Attack Complex A product of COMPLEMENT ACTIVATION cascade, regardless of the pathways, that forms transmembrane channels causing disruption of the target CELL MEMBRANE and cell lysis. It is formed by the sequential assembly of terminal complement components (COMPLEMENT C5B; COMPLEMENT C6; COMPLEMENT C7; COMPLEMENT C8; and COMPLEMENT C9) into the target membrane. The resultant C5b-8-poly-C9 is the "membrane attack complex" or MAC. Complement Complex C5b-9,Membrane Attack Complex,C 5b-9,C5b-8-poly-C9,C5b-9,Cytolytic Terminal Complement Complex,Terminal Complement Complex,C5b 8 poly C9,Complement Complex C5b 9,Complement Complex, Terminal,Complex, Terminal Complement

Related Publications

M Schönermark, and R Deppisch, and G Riedasch, and K Rother, and G M Hänsch
September 1991, The American journal of physiology,
M Schönermark, and R Deppisch, and G Riedasch, and K Rother, and G M Hänsch
January 1994, Experimental nephrology,
M Schönermark, and R Deppisch, and G Riedasch, and K Rother, and G M Hänsch
April 1990, Kidney international,
M Schönermark, and R Deppisch, and G Riedasch, and K Rother, and G M Hänsch
October 1997, Journal of immunology (Baltimore, Md. : 1950),
M Schönermark, and R Deppisch, and G Riedasch, and K Rother, and G M Hänsch
November 1989, The American journal of physiology,
M Schönermark, and R Deppisch, and G Riedasch, and K Rother, and G M Hänsch
July 1986, Clinical and experimental immunology,
M Schönermark, and R Deppisch, and G Riedasch, and K Rother, and G M Hänsch
May 1993, The Journal of clinical investigation,
M Schönermark, and R Deppisch, and G Riedasch, and K Rother, and G M Hänsch
March 2001, Kidney international,
M Schönermark, and R Deppisch, and G Riedasch, and K Rother, and G M Hänsch
November 1995, The American journal of physiology,
M Schönermark, and R Deppisch, and G Riedasch, and K Rother, and G M Hänsch
June 2006, Life sciences,
Copied contents to your clipboard!